Dr Richard John Annulli, MD | |
1037 Valley Rd, New Canaan, CT 06840-2818 | |
(203) 919-1836 | |
Not Available |
Full Name | Dr Richard John Annulli |
---|---|
Gender | Male |
Speciality | General Practice |
Location | 1037 Valley Rd, New Canaan, Connecticut |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1144590191 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 026958 (Connecticut) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Richard John Annulli, MD 1037 Valley Rd, New Canaan, CT 06840-2818 Ph: (203) 919-1836 | Dr Richard John Annulli, MD 1037 Valley Rd, New Canaan, CT 06840-2818 Ph: (203) 919-1836 |
News Archive
Dream journals being kept by students in a college psychology class have provided researchers with a unique look at how people experienced the events of 9/11, including the influence that television coverage of the World Trade Center attacks had on people's levels of stress.
pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has submitted a Marketing Authorization Application (MAA) to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (UK) for IluvienĀ®.
Nature can reset the clock in certain types of cancer and reverse many of the elements responsible for causing malignancy, reports a research team led by Whitehead Institute Member Rudolf Jaenisch, in collaboration with Lynda Chin from Dana Farber Cancer Institute.
ThromboGenics NV and BioInvent International AB today announced positive results from a Phase I trial of their novel anti-cancer monoclonal antibody TB-403 in patients with advanced solid tumours. The results were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, U.S. TB-403 was well tolerated with no reported dose limiting toxicity. These positive data support progression of TB-403 and further development.
› Verified 7 days ago